Verastem, Inc.
VS-7375
KRAS G12D solid tumors
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for VS-7375 in KRAS G12D solid tumors are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Complete enrollment in monotherapy expansion cohorts in 2H 2026.”